Dr. Patrick Treacy is Chairman of the Irish Association of Cosmetic Doctors and Irish Regional Representative of the 'Botox Myths and Facts' lecture by Dr. Patrick Treacy to American Academy of Aesthetic & Anit-Aging Medicine Mexico City 2012
Dr. Treacy is Chairman of the Irish Association of Cosmetic Doctors and Irish Regional Representative of the British Association of Cosmetic Medicine. He is European Medical Advisor to Network Lipolysis and the UK's largest cosmetic website Consulting Rooms. He practices cosmetic medicine in his clinics in Dublin, Cork, London and the Middle East.
20. t
In the first randomized, controlled study on the effect of
botulinum toxin—known commercially as Botox—on
depression, researchers investigated whether it might aid
patients with major depressive disorder who had not
responded to antidepressant medications. Participants in the
treatment group were given a single dose (consisting of five
injections) of botulinum toxin in the area of the face between
and just above the eyebrows, whereas the control group was
given placebo injections. Depressive symptoms in the
treatment group decreased 47 percent after six weeks, an
improvement that remained through the 16-week study
period. The placebo group had a 9 percent reduction in
symptoms. The findings appeared in May in the Journal of
Psychiatric Research.
26. tThe cosmetic effect of BTX-A on wrinkles was originally
documented by a plastic surgeon from Sacramento,
California, Dr. Richard Clark, and published in the
journal Plastic and Reconstructive Surgery in 1989.
40. t
Sweating
While treating patients with hemifacial spasm at Southend
Hospital in England in 1993, Khalaf Bushara and David Park were
the first to show botulinum toxin injections inhibit sweating.[10]
This was the first demonstration of nonmuscular use of BTX-A.
Bushara further showed the efficacy of botulinum toxin in treating
hyperhidrosis (excessive sweating). BTX-A was later approved for
the treatment of excessive underarm sweating. This is technically
known as severe primary axillary hyperhidrosis - excessive
underarm sweating with an unknown cause which cannot be
managed by topical agents.